Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Po Shun Lee"'
Autor:
Steven V Molinski, Saumel Ahmadi, Wan Ip, Hong Ouyang, Adriana Villella, John P Miller, Po‐Shun Lee, Kethika Kulleperuma, Kai Du, Michelle Di Paola, Paul DW Eckford, Onofrio Laselva, Ling Jun Huan, Leigh Wellhauser, Ellen Li, Peter N Ray, Régis Pomès, Theo J Moraes, Tanja Gonska, Felix Ratjen, Christine E Bear
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 9, Pp 1224-1243 (2017)
Abstract The combination therapy of lumacaftor and ivacaftor (Orkambi®) is approved for patients bearing the major cystic fibrosis (CF) mutation: ΔF508. It has been predicted that Orkambi® could treat patients with rarer mutations of similar “th
Externí odkaz:
https://doaj.org/article/63e4048262714fd991511c4196c2fb6d
Publikováno v:
American Journal of Therapeutics. 26:e103-e109
Background Sirolimus and propofol are both independently associated with the development of hypertriglyceridemia (HTG) during therapy. To date, there are no published reports describing synergistic or additive drug interaction resulting in HTG with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77cbf4407700aa0f14bfb9ba1b58849a
https://doi.org/10.1097/mjt.0000000000000461
https://doi.org/10.1097/mjt.0000000000000461
Autor:
Chenggang Li, Erik Zhang, Yang Sun, Po-Shun Lee, Yongzhong Zhan, Yanan Guo, Juan C Osorio, Ivan O Rosas, Kai-Feng Xu, David J Kwiatkowski, Jane J Yu
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e104809 (2014)
Tuberous sclerosis syndrome (TSC) is an autosomal dominant tumor suppressor gene syndrome affecting multiple organs, including renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM). LAM is a female-predominant interstitial lung disease c
Externí odkaz:
https://doaj.org/article/3e4c5f336bae4f4c9e51c1d13b9fd0e6
Autor:
Daniel Finley, Danijela Dukovski, J.P. Miller, Cecilia M. Bastos, Jeffery W. Kelly, Richard I. Morimoto, Benito Munoz, Randall W. King, F. Ulrich Hartl, Po Shun Lee, Adriana Villella, Marija Zecevic
Publikováno v:
Journal of cystic fibrosis
BACKGROUND: Cystic fibrosis (CF) is a recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. We previously described a first-in-class CFTR modulator that functions as an amplifier to selectively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8d08db66648517be6e46ada5b6addd
https://hdl.handle.net/21.11116/0000-0007-4DBE-E21.11116/0000-0007-4DC1-921.11116/0000-0007-4DC0-A
https://hdl.handle.net/21.11116/0000-0007-4DBE-E21.11116/0000-0007-4DC1-921.11116/0000-0007-4DC0-A
Autor:
Matthew Cullen, Cecilia M. Bastos, Lawrence Drew, Danijela Dukovski, Benito Munoz, Kenneth A. Giuliano, Shinichiro Wachi, Po-Shun Lee, Sheila Hauck, Olivia Green, Bradley D. Tait, John P. Miller
Publikováno v:
Slas Discovery
Cystic fibrosis (CF) is a lethal genetic disorder caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Despite recent groundbreaking approval of genotype-specific small-molecule drugs, a significant portion of CF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0ad75dc6470779f40014d6f7a23b0b
https://doi.org/10.1177/2472555217729790
https://doi.org/10.1177/2472555217729790
Autor:
Po-Shun Lee, Anna S K Wilhelmson, Anton P Hubner, Samuel B Reynolds, Dana A Gallacchi, Terry T Chiou, David J Kwiatkowski
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e14399 (2010)
mTORC1 (mammalian target of rapamycin complex 1) activation has been demonstrated in response to endotoxin challenge, but the mechanism and significance are unclear. We investigated the effect of mTORC1 suppression in an animal model of endotoxemia a
Externí odkaz:
https://doaj.org/article/a9c7fa2bab1b4ab7816a3510db84f54a
Autor:
Po-Shun Lee, Sanjay R Patel, David C Christiani, Ednan Bajwa, Thomas P Stossel, Aaron B Waxman
Publikováno v:
PLoS ONE, Vol 3, Iss 11, p e3712 (2008)
Depletion of the circulating actin-binding protein, plasma gelsolin (pGSN) has been described in septic patients and animals. We hypothesized that the extent of pGSN reduction correlates with outcomes of septic patients and that circulating actin is
Externí odkaz:
https://doaj.org/article/10e33f316a844029be1611be06b00d12
Autor:
Sunita Patel-Hett, Douglas Lazarus, Christian G. Peters, Amanda Leung, Sayaka Masuko, Dora E Kohnke, Lindsay Tomczak, Angelique Meredith, Brad Dykstra, Marcus Lehmann, Silvia Giannini, Dean Falb, Ryan Carpenter, Po-Shun Lee, Sophia Pete, Ashley J Russo
Publikováno v:
Blood. 138:1001-1001
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts ( Current treatment strategies for ITP include non-specific immunosuppression (steroids, rituximab), inhibition of platelet clearance (immunoglobulins, splen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b7f4593ede3ca470c693bd8ec511104
https://doi.org/10.1182/blood-2021-150823
https://doi.org/10.1182/blood-2021-150823
Autor:
J.P. Miller, Ling Jun Huan, Saumel Ahmadi, Felix Ratjen, Régis Pomès, Paul D. W. Eckford, Hong Ouyang, Leigh Wellhauser, Christine E. Bear, Adriana Villella, Ellen Li, Theo J. Moraes, Kethika Kulleperuma, Peter N. Ray, Michelle Di Paola, Onofrio Laselva, Steven Molinski, Wan Ip, Po-Shun Lee, Tanja Gonska, Kai Du
Publikováno v:
EMBO Molecular Medicine
The combination therapy of lumacaftor and ivacaftor (Orkambi ® ) is approved for patients bearing the major cystic fibrosis (CF) mutation: ΔF508 . It has been predicted that Orkambi ® could treat patients with rarer mutations of similar “theraty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aaadb2a10accd16a9627ce93c3d4764
http://europepmc.org/articles/PMC5582412
http://europepmc.org/articles/PMC5582412
Autor:
Po-Shun Lee, Hwee-Yeong Ng, Shang-Chih Liao, Wen-Chin Lee, Yueh-Ting Lee, Chien-Te Lee, Terry Ting-Yu Chiou, Yu-Yin Kao
Publikováno v:
International Journal of Medical Sciences
Background: Vascular calcification (VC) is a key process associated with cardiovascular mortality in dialysis patients. Gelsolin is an actin-binding protein that can modulate inflammation, correlated inversely with hemodialysis (HD) mortality and inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84984ec1b21fd97b1794d4d4bfa83404
http://europepmc.org/articles/PMC4764774
http://europepmc.org/articles/PMC4764774